Zebra Technologies (ZBRA) Numbers Signals, Lannett Company (LCI) FDA Green Light for Bioequivalent Diazepam Oral Solution
ZBRA reported that it expects to report sales for the first quarter of 2014 in the range of $287,000,000 to $289,000,000, or 21% over the $236,937,000 in sales reported for the same period the prior year, while ZBRA's earnings are expected in a range of $0.79 to $0.82 per share, up approximately 74% from $0.46 per share for the first quarter of 2013.
ZBRA also announced that it will acquire Motorola's Enterprise business for $3.45 billion in an all-cash transaction.
- Published: 15 April 2014
- Written by Martin Scareme